Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 809

1.

A Method for Approximating Future Entry of Generic Drugs.

Beall RF, Darrow JJ, Kesselheim AS.

Value Health. 2018 Dec;21(12):1382-1389. doi: 10.1016/j.jval.2018.04.1827. Epub 2018 Jun 11.

PMID:
30502781
2.

Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.

Hwang TJ, Orenstein L, Kesselheim AS, Bourgeois FT.

JAMA Pediatr. 2018 Nov 19. doi: 10.1001/jamapediatrics.2018.3416. [Epub ahead of print]

PMID:
30452498
3.

Predictors of Drug Shortages and Association with Generic Drug Prices: A Retrospective Cohort Study.

Dave CV, Pawar A, Fox ER, Brill G, Kesselheim AS.

Value Health. 2018 Nov;21(11):1286-1290. doi: 10.1016/j.jval.2018.04.1826. Epub 2018 May 18.

PMID:
30442275
4.

The US Biosimilar Market: Stunted Growth and Possible Reforms.

Sarpatwari A, Barenie R, Curfman G, Kesselheim AS.

Clin Pharmacol Ther. 2018 Nov 11. doi: 10.1002/cpt.1285. [Epub ahead of print] Review.

PMID:
30415479
5.

The Tax Cuts and Jobs Act of 2017 and the Pharmaceutical Industry.

Sinha MS, Kesselheim AS.

J Law Med Ethics. 2018 Sep;46(3):806-808. doi: 10.1177/1073110518804246. No abstract available.

PMID:
30336090
6.

The promise of ESCAT: a new system for evaluating cancer drug-target pairs.

Gyawali B, Kesselheim AS.

Nat Rev Clin Oncol. 2018 Oct 13. doi: 10.1038/s41571-018-0110-3. [Epub ahead of print] No abstract available.

PMID:
30317250
7.

Internal Medicine Physicians' Financial Relationships with Industry: An Updated National Estimate.

Kesselheim AS, Woloshin S, Lu Z, Tessema FA, Ross KM, Schwartz LM.

J Gen Intern Med. 2018 Oct 5. doi: 10.1007/s11606-018-4688-z. [Epub ahead of print] No abstract available.

PMID:
30291605
8.

A Systematic Review Of The Food And Drug Administration's 'Exception From Informed Consent' Pathway.

Feldman WB, Hey SP, Kesselheim AS.

Health Aff (Millwood). 2018 Oct;37(10):1605-1614. doi: 10.1377/hlthaff.2018.0501.

PMID:
30273035
9.

Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012.

Sinha MS, Najafzadeh M, Rajasingh EK, Love J, Kesselheim AS.

JAMA Intern Med. 2018 Nov 1;178(11):1458-1466. doi: 10.1001/jamainternmed.2018.3933.

PMID:
30264138
10.

General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment.

Najafzadeh M, Schneeweiss S, Choudhry NK, Avorn J, Gagne JJ.

Patient. 2018 Sep 21. doi: 10.1007/s40271-018-0329-1. [Epub ahead of print]

PMID:
30242575
11.

Changes in Drug Pricing After Drug Shortages in the United States.

Hernandez I, Sampathkumar S, Good CB, Kesselheim AS, Shrank WH.

Ann Intern Med. 2018 Sep 18. doi: 10.7326/M18-1137. [Epub ahead of print] No abstract available.

PMID:
30242373
12.

The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later.

Avorn J, Kesselheim A, Sarpatwari A.

N Engl J Med. 2018 Sep 20;379(12):1097-1099. doi: 10.1056/NEJMp1803910. No abstract available.

13.

Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study.

Kim DH, Glynn RJ, Avorn J, Lipsitz LA, Rockwood K, Pawar A, Schneeweiss S.

J Gerontol A Biol Sci Med Sci. 2018 Aug 27. doi: 10.1093/gerona/gly197. [Epub ahead of print]

PMID:
30165612
14.

Does Helicobacter pylori eradication therapy to prevent gastric cancer increase all-cause mortality?

Gyawali B, Kesselheim AS, D'Andrea E.

Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31772. [Epub ahead of print] No abstract available.

PMID:
30152520
15.

Government Patent Use to Address the Rising Cost of Naloxone: 28 U.S.C. ยง 1498 and Evzio.

Wang A, Kesselheim AS.

J Law Med Ethics. 2018 Jun;46(2):472-484. doi: 10.1177/1073110518782954.

PMID:
30146993
16.

Defining "True and Non-Misleading" for Pharmaceutical Promotion.

Hey SP, Kesselheim AS.

J Law Med Ethics. 2018 Jun;46(2):552-554. doi: 10.1177/1073110518782970. No abstract available.

PMID:
30146990
17.

The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents.

Darrow JJ, Beall RF, Kesselheim AS.

Appl Health Econ Health Policy. 2018 Aug 24. doi: 10.1007/s40258-018-0420-8. [Epub ahead of print]

PMID:
30141133
18.

Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.

Sacks CA, Lee CC, Kesselheim AS, Avorn J.

JAMA. 2018 Aug 21;320(7):650-656. doi: 10.1001/jama.2018.11439.

PMID:
30140875
19.

Longitudinal Trends and Variation in Antipsychotic Use in Older Adults After Cardiac Surgery.

Kim DH, Mahesri M, Bateman BT, Huybrechts KF, Inouye SK, Marcantonio ER, Herzig SJ, Ely EW, Pisani MA, Levin R, Avorn J.

J Am Geriatr Soc. 2018 Aug;66(8):1491-1498. doi: 10.1111/jgs.15418. Epub 2018 Aug 19.

PMID:
30125337
20.

Expansion of the Priority Review Voucher Program Under the 21st Century Cures Act: Implications for Innovation and Public Health.

Sinha MS, Jain N, Hwang T, Kesselheim AS.

Am J Law Med. 2018 May;44(2-3):329-341. doi: 10.1177/0098858818789430. No abstract available.

PMID:
30106661

Supplemental Content

Loading ...
Support Center